Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short‐term open, randomized multicenter study

Background : The objective of this open randomized clinical study was to compare the short‐term efficacy and safety of three alpha‐1 blockers, prazosin, terazosin and tamsulosin, in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

[1]  D. Jensen.  Uninhibited neurogenic bladder treated with Prazosin. , 1981, Scandinavian journal of urology and nephrology.

[2]  K. Andersson,et al.  Effects of prazosin in patients with benign prostatic obstruction. , 1983, The Journal of urology.

[3]  K. Kawabe,et al.  Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy , 1990 .

[4]  H. Lepor,et al.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. , 1992, The Journal of urology.

[5]  J. Shimazaki,et al.  Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study. , 1993, Urologia internationalis.

[6]  P. Blondin,et al.  Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. , 1993, British journal of urology.

[7]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[8]  Y. Homma,et al.  Estimate Criteria for Efficacy of Treatment in Benign Prostatic Hyperplasia , 1996, International journal of urology : official journal of the Japanese Urological Association.

[9]  S. Kaplan,et al.  Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia. , 1996, Urology.

[10]  E. Lee,et al.  Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. , 1997, British journal of urology.

[11]  P. Abrams,et al.  A dose‐ranging study of the efficacy and safety of tamsulosin, the first prostate‐selective a1A‐adrenoceptor antagonist*, in patients with benign prostatic obstruction , 1997 .

[12]  M. Wyllie,et al.  Prostatic α1‐adrenoceptors and uroselectivity , 1997 .

[13]  T. Moreland,et al.  A Double-Blind Comparison of Terazosin and Tamsulosin on Their Differential Effects on Ambulatory Blood Pressure and Nocturnal Orthostatic Stress Testing , 1998, European Urology.